{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:13:41Z","timestamp":1785402821046,"version":"3.56.0"},"reference-count":58,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>IgA nephropathy (IgAN) is a primary glomerular disease with various clinical features, disease progression, and therapeutic responses that affects people worldwide. Currently, risk stratification depends primarily on clinical variables, together with the Oxford MEST-C classification, which indicates structural damage. However, these approaches only provide a limited explanation of the molecular mechanisms responsible for the disease. Recent proteomic discoveries have enabled researchers to characterize proteins not only in blood plasma and urine but also in kidney tissues, opening new avenues for understanding the underlying biology of IgAN. Our review addresses existing findings in plasma proteomic studies and, at the same time, brings into the picture developments in urinary and tissue proteomic profiling, thereby demonstrating that molecular profiling has been essential for further understanding of IgAN pathogenesis. Several research studies highlight complement system dysregulation, immune system overactivity, extracellular matrix remodeling, and metabolic disturbances as the leading factors linked to disease activity and progression. Even after many years in biomarker discovery, the development and clinical application of single plasma-based molecules as markers for disease detection remain challenging. Proteomic signatures based on the various processes involved in a single disease consistently outperform single protein identification in describing complexity and distinguishing molecular endotypes. We also present the current status of proteomic-based profiling methods, cross-linking proteomics with other data sources, and the remaining clinical application barriers. Through the development of this technology, proteomics has not only enabled the discovery of new biomarkers but also provided a framework for viewing IgAN as a heterogeneous disease comprising distinct molecular endotypes. Overall, current evidence indicates that proteomics is evolving from biomarker discovery toward molecular disease classification, with the potential to improve prognostication, guide mechanism-based therapeutic selection, and advance precision nephrology in IgAN.<\/jats:p>","DOI":"10.3390\/cells15151373","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:09:42Z","timestamp":1785398982000},"page":"1373","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma Proteomics in IgA Nephropathy: From Circulating Biomarkers to Molecular Endotypes"],"prefix":"10.3390","volume":"15","author":[{"given":"Charlotte","family":"Delrue","sequence":"first","affiliation":[{"name":"Department of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2333-1630","authenticated-orcid":false,"given":"Stefania","family":"Marzocco","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3072-5080","authenticated-orcid":false,"given":"Rafael Noal","family":"Moresco","sequence":"additional","affiliation":[{"name":"Graduate Program in Pharmaceutical Sciences, Center of Health Sciences, Federal University of Santa Maria, Santa Maria 97105-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-4390","authenticated-orcid":false,"given":"Marijn M.","family":"Speeckaert","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium"},{"name":"Research Foundation-Flanders (FWO), 1000 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA Nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(16)00272-5","article-title":"Primary Glomerulonephritides","volume":"387","author":"Floege","year":"2016","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Barratt, J., Lafayette, R.A., and Floege, J. (2024). Therapy of IgA Nephropathy: Time for a Paradigm Change. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1461879"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"151571","DOI":"10.1016\/j.semnephrol.2025.151571","article-title":"IgA Vasculitis and IgA Nephropathy: Two Sides of the Same Coin?","volume":"44","author":"Pillebout","year":"2024","journal-title":"Semin. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molimm.2019.07.017","article-title":"The Role of Complement in IgA Nephropathy","volume":"114","author":"Tortajada","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ekir.2017.11.015","article-title":"Progressive IgA Nephropathy Is Associated with Low Circulating Mannan-Binding Lectin\u2013Associated Serine Protease-3 (MASP-3) and Increased Glomerular Factor H\u2013Related Protein-5 (FHR5) Deposition","volume":"3","author":"Troldborg","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000382134","article-title":"New Insights into the Pathogenesis of IgA Nephropathy","volume":"1","author":"Novak","year":"2015","journal-title":"Kidney Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13578-021-00706-1","article-title":"Single-Cell RNA-Sequencing Reveals Distinct Immune Cell Subsets and Signaling Pathways in IgA Nephropathy","volume":"11","author":"Zeng","year":"2021","journal-title":"Cell Biosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105961","DOI":"10.1016\/j.isci.2023.105961","article-title":"Proteomic Profiling of IgA Nephropathy Reveals Distinct Molecular Prognostic Subtypes","volume":"26","author":"Chen","year":"2023","journal-title":"iScience"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/ckj\/sfad211","article-title":"Urinary Peptidome Analysis in CKD and IgA Nephropathy","volume":"16","author":"Li","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-Release Budesonide versus Placebo in Patients with IgA Nephropathy (NEFIGAN): A Double-Blind, Randomised, Placebo-Controlled Phase 2b Trial","volume":"389","author":"Barratt","year":"2017","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and Safety of a Targeted-Release Formulation of Budesonide in Patients with Primary IgA Nephropathy (NefIgArd): 2-Year Results from a Randomised Phase 3 Trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and Safety of Sparsentan versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results from a Randomised, Active-Controlled, Phase 3 Trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Paunas, F.T.I., Finne, K., Leh, S., Marti, H.-P., Berven, F., and Vikse, B.E. (2022). Proteomic Signature of Tubulointerstitial Tissue Predicts Prognosis in IgAN. BMC Nephrol., 23.","DOI":"10.1186\/s12882-022-02736-4"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"19311","DOI":"10.1038\/s41598-024-70209-9","article-title":"Proteomic Analysis of Laser Captured Tubular Tissues Reveals Complement Activation and Mitochondrial Dysfunction in Autoimmune Related Kidney Diseases","volume":"14","author":"Xiao","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts, I.S.D., Cook, H.T., Troyanov, S., Alpers, C.E., Amore, A., Barratt, J., Berthoux, F., Bonsib, S., and Bruijn, J.A. (2009). The Oxford Classification of IgA Nephropathy: Pathology Definitions, Correlations, and Reproducibility. Kidney Int., 76, 546\u2013556.","DOI":"10.1038\/ki.2009.168"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The Pathophysiology of IgA Nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00281-021-00871-y","article-title":"The Mucosal Immune System and IgA Nephropathy","volume":"43","author":"Gesualdo","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford Classification of IgA Nephropathy 2016: An Update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int."},{"key":"ref_21","unstructured":"A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran, D.C., Coppo, R., Cook, H.T., Feehally, J., Roberts, I.S.D., Troyanov, S., Alpers, C.E., Amore, A., and Barratt, J. (2009). The Oxford Classification of IgA Nephropathy: Rationale, Clinicopathological Correlations, and Classification. Kidney Int., 76, 534\u2013545."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford Classification of IgA Nephropathy in Cohorts with Different Presentations and Treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/ndt\/gfy337","article-title":"Reproducibility of the Oxford Classification of Immunoglobulin A Nephropathy, Impact of Biopsy Scoring on Treatment Allocation and Clinical Relevance of Disagreements: Evidence from the VALidation of IGA Study Cohort","volume":"34","author":"Bellur","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a New International Risk-Prediction Tool in IgA Nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of New Risk Loci for IgA Nephropathy Implicates Genes Involved in Immunity against Intestinal Pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-Wide Association Study Identifies Susceptibility Loci for IgA Nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12014-022-09387-5","article-title":"LC-MS\/MS Based Metabolomics and Proteomics Reveal Candidate Biomarkers and Molecular Mechanism of Early IgA Nephropathy","volume":"19","author":"Zhang","year":"2022","journal-title":"Clin. Proteom."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature19949","article-title":"Mass-Spectrometric Exploration of Proteome Structure and Function","volume":"537","author":"Aebersold","year":"2016","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41576-020-0258-4","article-title":"mRNAs, Proteins and the Emerging Principles of Gene Expression Control","volume":"21","author":"Buccitelli","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","article-title":"On the Dependency of Cellular Protein Levels on mRNA Abundance","volume":"165","author":"Liu","year":"2016","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cels.2016.02.015","article-title":"Plasma Proteome Profiling to Assess Human Health and Disease","volume":"2","author":"Geyer","year":"2016","journal-title":"Cell Syst."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2215\/CJN.07420619","article-title":"Proteomics and Metabolomics in Kidney Disease, Including Insights into Etiology, Treatment, and Prevention","volume":"15","author":"Dubin","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"MSB178126","DOI":"10.15252\/msb.20178126","article-title":"Data-independent Acquisition-based SWATH-MS for Quantitative Proteomics: A Tutorial","volume":"14","author":"Ludwig","year":"2018","journal-title":"Mol. Syst. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Assarsson, E., Lundberg, M., Holmquist, G., Bj\u00f6rkesten, J., Bucht Thorsen, S., Ekman, D., Eriksson, A., Rennel Dickens, E., Ohlsson, S., and Edfeldt, G. (2014). Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095192"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E.N., Carter, J., Dalby, A.B., Eaton, B.E., and Fitzwater, T. (2010). Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015004"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17208","DOI":"10.1021\/acsomega.4c07827","article-title":"Proteomic Insights into IgA Nephropathy: A Comprehensive Analysis of Differentially Expressed Proteins in the Kidney","volume":"10","author":"Huang","year":"2025","journal-title":"ACS Omega"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100550","DOI":"10.1016\/j.mcpro.2023.100550","article-title":"Proteomics: Progress and Promise of High-Throughput Proteomics in Chronic Kidney Disease","volume":"22","author":"Schlosser","year":"2023","journal-title":"Mol. Cell. Proteom."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00281-021-00882-9","article-title":"Complement Activation in IgA Nephropathy","volume":"43","author":"Cook","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1681\/ASN.2014010096","article-title":"Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy","volume":"26","author":"Zhu","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"sfag176","DOI":"10.1093\/ckj\/sfag176","article-title":"Multi-Omics Triangulation Identifies Complement Factor H as a Genetically Supported Protective Factor in IgA Nephropathy","volume":"19","author":"Shao","year":"2026","journal-title":"Clin. Kidney J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.kint.2017.03.043","article-title":"Circulating Complement Factor H\u2013Related Proteins 1 and 5 Correlate with Disease Activity in IgA Nephropathy","volume":"92","author":"Beckwith","year":"2017","journal-title":"Kidney Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.ekir.2025.07.005","article-title":"Proteomic Analysis of Circulating IgA1-Containing Immune Complexes in Patients with IgA Nephropathy","volume":"10","author":"Cunningham","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"45375","DOI":"10.1038\/s41598-025-29024-z","article-title":"Complement Proteins Associated with Circulatory and Glomerular IgA-Containing Immune Complexes in Patients with IgA Nephropathy","volume":"15","author":"Tsuji","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Cheung, C.K., Barratt, J., Liew, A., Zhang, H., Tesar, V., and Lafayette, R. (2024). The Role of BAFF and APRIL in IgA Nephropathy: Pathogenic Mechanisms and Targeted Therapies. Front. Nephrol., 3.","DOI":"10.3389\/fneph.2023.1346769"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00011-025-02131-3","article-title":"Multiple Circulating Inflammatory Proteins Are Associated with Pathological Lesions and Kidney Function Decline in IgA Nephropathy","volume":"74","author":"Kobayashi","year":"2025","journal-title":"Inflamm. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"109204","DOI":"10.1016\/j.jdiacomp.2025.109204","article-title":"Soluble Tumor Necrosis Factor Receptors (sTNFRs) as Biomarkers for Diabetic Kidney Disease","volume":"40","author":"Moroney","year":"2026","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA Nephropathy\u2014Interim Analysis of a Phase 3 Trial","volume":"394","author":"Perkovic","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Tian, Z., Yang, Y., Huang, M., Fang, Z., Mei, J., Li, Y., Tang, L., Li, Y., and Li, Y. (2025). Efficacy and Safety of BAFF\/APRIL Dual Antagonists in IgA Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BMC Nephrol., 27.","DOI":"10.1186\/s12882-025-04689-w"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Rizk, D.V., Maillard, N., Julian, B.A., Knoppova, B., Green, T.J., Novak, J., and Wyatt, R.J. (2019). The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00504"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12014-015-9092-7","article-title":"Urinary Proteomics in Chronic Kidney Disease: Diagnosis and Risk of Progression beyond Albuminuria","volume":"12","author":"Vikse","year":"2015","journal-title":"Clin. Proteom."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ndt\/gfaa307","article-title":"Urine Proteomics for Prediction of Disease Progression in Patients with IgA Nephropathy","volume":"37","author":"Rudnicki","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1093\/ndt\/gfad125","article-title":"Dynamics of Urine Proteomics Biomarker and Disease Progression in Patients with IgA Nephropathy","volume":"38","author":"Peters","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kalantari, S., Rutishauser, D., Samavat, S., Nafar, M., Mahmudieh, L., Rezaei-Tavirani, M., and Zubarev, R.A. (2013). Urinary Prognostic Biomarkers and Classification of IgA Nephropathy by High Resolution Mass Spectrometry Coupled with Liquid Chromatography. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080830"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wang, D., Wu, C., Chen, S., Li, Y., Wang, L., Zhang, Y., and Li, G. (2023). Urinary Complement Profile in IgA Nephropathy and Its Correlation with the Clinical and Pathological Characteristics. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1117995"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/modpathol.2011.205","article-title":"Characterization of Glomerular Diseases Using Proteomic Analysis of Laser Capture Microdissected Glomeruli","volume":"25","author":"Satoskar","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12953-024-00231-2","article-title":"Spatial Proteomics: Unveiling the Multidimensional Landscape of Protein Localization in Human Diseases","volume":"22","author":"Wu","year":"2024","journal-title":"Proteome Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.aat5031","article-title":"Spatiotemporal Immune Zonation of the Human Kidney","volume":"365","author":"Stewart","year":"2019","journal-title":"Science"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1373\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:25:18Z","timestamp":1785399918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":58,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cells15151373"],"URL":"https:\/\/doi.org\/10.3390\/cells15151373","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}